Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

The Access Industries and Eli Lilly-backed genetic drug developer floated at the top of its range having increased the number of shares in the offering by 60%.

Auriens-backed Cera boosted its overall funding to $91m as it seeks both domestic and international expansion for its home elderly care service.

Cyagen's Chinese research product spinoff raised $40.5m and will use the funding to grow its business along with its contract research services.

Stem cell medicine and skincare product developer has added $12.5m as part of a series B-2 round that will come after $15m from SFC two years ago.

Takeda has bought celiac disease therapy developer PvP Biologics, three years after acquiring an option to buy it in return for $35m in financing.

Existing investor Hadasit Bio-Holdings took part in a round that pushed the immuno-oncology therapy developer's overall funding tally to more than $35m.

Cleveland Clinic and Ascension Ventures contributed to a $15.8m round for Cardionomic, which is developing a neuromodulation system to treat heart failure.

The blood test developer took in $165m through a series B round led by SoftBank Vision Fund 2 that came three years after a Tencent-backed series A.

Manufacturing partner WuXi Biologics participated in a series A round for the startup, which aims to transfer human biopharmaceutical practices to animal drug development.